Medulloblastoma recurrent – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 11:24:44 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Medulloblastoma recurrent – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 A study of RVU120 and everolimus for children with recurrent or progressive medulloblastoma https://clinicaltrials.eu/trial/a-study-of-rvu120-and-everolimus-for-children-with-recurrent-or-progressive-medulloblastoma/ Wed, 29 Apr 2026 15:10:06 +0000 https://clinicaltrials.eu/trial/a-study-of-rvu120-and-everolimus-for-children-with-recurrent-or-progressive-medulloblastoma/ This study focuses on children with medulloblastoma, which is a type of brain tumor. The research specifically involves patients with Group 3 or Group 4 medulloblastoma that has either returned after previous treatment or is continuing to grow. The purpose of the study is to evaluate the safety and the correct dosage of a new treatment combination.

The treatment involves two main medications: RVU120, which is a CDK8 inhibitor, and everolimus. RVU120 is also referred to by its chemical name, SEL120 monohydrochloride. These medications are taken by mouth in the form of capsules or tablets. The study will look at how these drugs work both by themselves and when used together.

During the study, participants will receive these medications to help researchers understand how well the body handles the drugs and to find the maximum dose that can be given safely. The process involves monitoring how the medications move through the body and observing any side effects that may occur during the treatment period.

]]> Study of Axitinib and Etoposide for Children and Young Adults with Refractory or Relapsing Medulloblastoma and Ependymoma https://clinicaltrials.eu/trial/study-of-axitinib-and-etoposide-for-children-and-young-adults-with-refractory-or-relapsing-medulloblastoma-and-ependymoma/ Wed, 29 Apr 2026 14:58:34 +0000 https://clinicaltrials.eu/trial/study-of-axitinib-and-etoposide-for-children-and-young-adults-with-refractory-or-relapsing-medulloblastoma-and-ependymoma/ This clinical trial is focused on studying two types of brain tumors: medulloblastoma and ependymoma. These are serious conditions that can occur in children and young adults. The study is testing a combination of two medications: axitinib, known by its brand name Inlyta, and etoposide. Axitinib is a medication that helps to block certain proteins that can promote cancer growth, while etoposide is a chemotherapy drug that helps to stop cancer cells from dividing and growing.

The purpose of this study is to find out how well these medications work together in treating patients whose tumors have not responded to standard treatments or have returned after treatment. The study will be conducted in two stages. In the first stage, researchers will determine the best dose of axitinib to use with a fixed dose of etoposide. In the second stage, they will evaluate how effective this combination is in preventing the tumors from growing or spreading further.

Participants in the study will receive the medications and be monitored over time to see how their tumors respond. The study will also look at the safety of the treatment and any side effects that may occur. This research aims to provide new insights into treatment options for children and young adults with these challenging types of brain tumors.

]]> Study on the Safety and Efficacy of AloCelyvir for Children, Adolescents, and Young Adults with Diffuse Intrinsic Pontine Glioma or Medulloblastoma. https://clinicaltrials.eu/trial/study-on-the-safety-and-efficacy-of-alocelyvir-for-children-adolescents-and-young-adults-with-diffuse-intrinsic-pontine-glioma-or-medulloblastoma/ Wed, 29 Apr 2026 14:24:42 +0000 https://clinicaltrials.eu/trial/study-on-the-safety-and-efficacy-of-alocelyvir-for-children-adolescents-and-young-adults-with-diffuse-intrinsic-pontine-glioma-or-medulloblastoma/ This clinical trial is focused on studying two types of brain tumors in young patients: Diffuse Intrinsic Pontine Glioma (DIPG) and Medulloblastoma. DIPG is a rare and aggressive brain tumor found in the brainstem, while Medulloblastoma is a cancerous brain tumor that can occur in the cerebellum. The treatment being tested in this study is called AloCelyvir, which is a special type of cell therapy. It involves using cells from bone marrow that have been modified with a virus called ICOVIR-5 to potentially help fight the cancer.

The purpose of the study is to evaluate the safety and effectiveness of AloCelyvir in treating these conditions. For patients with newly diagnosed DIPG, the study will test the combination of AloCelyvir with radiotherapy, which is a treatment that uses high-energy rays to target and kill cancer cells. For those with Medulloblastoma that has returned or worsened, the study will test AloCelyvir on its own. Participants will receive the treatment through an intravenous infusion, which means the medicine is given directly into a vein.

The study will involve regular visits to monitor the participants’ health and response to the treatment. The goal is to understand how well the treatment works and to ensure it is safe for use in children, adolescents, and young adults. The trial will also look at how the body reacts to the treatment over time, including any side effects that may occur. This research aims to provide new insights into potential treatments for these challenging brain tumors.

]]>